BEAM · Beam Therapeutics Inc.
Beam Therapeutics (BEAM) — clinical-stage biotech developing precision genetic medicines via base editing. This page aggregates recent SEC filings (10-Q/10-K), a short market commentary, our current sell recommendation, and active research items. Items are factual extracts from public filings and trading activity; not investment advice.
Recent proof-backed thesis calls
We highlighted multiple recent company filings (10-Qs for 2025-06-30, 2025-09-30, 2026-03-31 and the 2025 10-K). Filings show continued R&D spend, collaboration revenue variability, and an enlarged share count following a March 2025 offering. Key balance-sheet items: cash, cash equivalents and marketable securities totaled about $1.2B as of 2026-03-31, and the company reported continued operating losses and an accumulated deficit.
The source is a one-line conceptual statement about aging as a drift from optimal gene expression. It provides no company, product, catalyst, timing, or investable details, so it is not directly actionable for trading without additional context (e.g., specific targets, modalities, clinical readouts, or firms).
The provided excerpt of Beam Therapeutics’ (BEAM) 10-Q for the quarter ended 2026-03-31 contains only the cover page/filing compliance information (issuer details, exchange listing, checkboxes for filing status). It does not include financial statements, MD&A, cash runway, guidance, pipeline updates, risk factors, or any quantitative/disclosive items that would support a tradable view.
Short listing for a YouTube interview filmed at the 2026 Abundance360 Summit with Ben Lamm (Colossal) titled “AI + Synthetic Biology: The Most Transformative Technology in Human History.” The listing notes the video but the transcript could not be retrieved. Content likely promotes Colossal’s synthetic biology/de‑extinction work and argues AI+synthbio is transformational. No new corporate filings, financing, or measurable operational updates are present in the item.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
The provided excerpt is only the cover/boilerplate portion of Beam Therapeutics’ (BEAM) 10-K for FY ended 2025-12-31 (listing details, exchange, reporting status). It contains no financial statements, MD&A, risk factor changes, guidance, pipeline updates, cash runway, or material events; therefore it is not directly actionable for trading based on the text supplied.
The provided excerpt is only the cover/header portion of Beam Therapeutics’ 10-Q (Form type, period ended, listing info, compliance checkboxes) and contains no financial results, guidance, pipeline/clinical updates, risks, or MD&A details. As-is, it does not support a directional trading thesis beyond noting a routine filing.
The provided text is only the cover/header portion of Beam Therapeutics’ Form 10‑Q for the quarter ended 2025‑06‑30. It contains no financial statements, guidance, clinical/program updates, cash runway, risk factor changes, or other performance details, so it offers limited actionable trading signal beyond confirming BEAM is a Nasdaq-listed SEC reporting issuer that filed required reports.
Latest market-close explanation
Latest trading note: BEAM ticked up to $31.85 (+0.85%) on a ~62% volume increase without company-specific news. Price tested the $32.5 area and faded into the close — a pattern consistent with flow-driven sector interest or technical probing rather than a fundamental breakout. Watch for follow-through above ~$32.5 on sustained volume or a fade below ~$31.
What most likely happened - No company-specific news or earnings today, yet BEAM slipped modestly (close -1.29%) on volume that was ~18% below yesterday — a sign the move lacked strong conviction. - Intraday action showed a roughly $1.8 range (low $28.67, high $30.48) with the stock closing below both the open ($29.46) and prior close ($29.41), suggesting mild profit-taking or sector drift rather than a catalytic sell-off. What to watch next - Volume and conviction: rising volume on follow-through down would be more bearish; muted volume or a bounce on higher volume would reduce near-term downside risk. - Key technical levels: near-term support around $28–28.50 (today’s low and recent congestion); resistance near $30.50. A decisive break of either level with volume would guide direction. - Sector and market drivers: biotech-wide sentiment, NASDAQ moves, and any FDA/clinical-readout calendar for base-editing or gene-editing peers can move BEAM even without company news. - Company catalysts: upcoming trial readouts, regulatory updates, partnerships, or financing announcements. Watch SEC filings and press releases for those. - Options/flow: unusual option activity or increased short interest could accelerate moves—monitor if you need to manage risk. Bottom line: today’s small decline on below-average volume points to low conviction rather than a fresh negative development. Pay attention to volume-confirmed breaks of $28–$30.50 and biotech/market headlines for the next directional trigger.
Current stance
Current recommendation: sell. Rationale is filing- and results-driven: recent periodic reports show persistent losses, ongoing cash burn from R&D, and dilution events (equity offering). Market activity and filings imply heightened financing and execution risk; see detailed explanations below.
- sell via BEAM 10-Q report for 2026-03-31 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- sell via BEAM 10-K report for 2025-12-31 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- sell via BEAM 10-Q report for 2025-09-30 from https://www.sec.gov/edgar/search/ (confidence 0.60)
Top authors on this asset
Active and historical ticker theses
Active research items include routine SEC periodic reports (10-Qs and 10-K) that supply financial statements and MD&A but — in the provided excerpts — often only include cover/header pages. These filings confirm listing and reporting status but, where full statements are available, show rising operating expenses, collaboration revenue swings, and financing activity (public offering, ATM program, and a credit facility drawn in Feb 2026).
No high-conviction trade signal can be extracted from the provided 10‑Q header alone.
BEAM 10-Q report for 2025-09-30
BEAM 10-K report for 2025-12-31
BEAM 10-Q report for 2026-03-31
Unlock full asset monitoring
Read the cited SEC filings for full financials and risk disclosures (links available in source records). Monitor upcoming clinical or partnering announcements, SEC filings for financing activity, and volume/price action for confirmation of any trend change.